![]() |
|
|
Vol. 295, Issue 2, 717-723, November 2000
Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., Yokohama,
Japan (N.O., I.K.); and Graduate School of Pharmaceutical Sciences,
University of Tokyo, Tokyo, Japan (Y.S.)
ME3229 is an ester-type prodrug of a glycoprotein IIb/IIIa receptor
antagonist ME3277. In our previous study, it was shown that only a
small part of the drug taken up into the enterocytes reached the
mesenteric vein, mainly due to transporter-mediated efflux of its
hydrolyzed metabolites formed in the cells. To characterize the efflux
transport system for the metabolites, the transport of the diacid
metabolite ME3277 and the monoacid metabolites PM-10 and PM-11 were
studied. ME3277 and PM-10 were preferentially transported in the
serosal-to-mucosal direction across the rat small intestine in the
presence of glucose. Permeability of ME3277 across monolayer of Caco-2
cells with P-glycoprotein (P-gp) and indomethacin-sensitive efflux pump
expression did not show any directionality and verapamil, an inhibitor
of P-gp, and indomethacin did not affect the permeability of ME3277
across rat intestinal tissue. Directional transport was not site
specific and was observed in the Eisai hyperbilirubinemic rat
whose canalicular multispecific organic anion transporter/multidrug resistance-associated protein (cMOAT/MRP2) is hereditarily defective as
well as in normal rats. The efflux transport of ME3277 was inhibited by
1-naphthol, 1-choloro-2,4-dinitrobenzene, and sulfobromophthalein, and
efflux of ME3277 and monoacid metabolites from intestinal tissue
preloaded with ME3229 fell in the presence of 1-naphthol and
sulfobromophthalein. These results demonstrate that mono- and diacid
metabolites of ME3229 were pumped out into the gut lumen by an
energy-dependent transport system located on the mucosal membrane of
intestinal tissue and distinct from either P-gp, indomethacin-sensitive efflux pump or canalicular multispecific organic anion
transporter/MRP2. An inhibition study suggested that this unknown
transporter has a substrate specificity similar to that of MRP
transporter families.
This article has been cited by other articles:
![]() |
N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF] |
||||